Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Bone tumors

New treatment impulses for osteosarcoma fuel hope

  • Uncategorized
  • 3 minute read

Osteosarcoma is one of the most common primary malignant bone tumors in children and young adults with a high risk of bone and lung metastases. Despite recent advances in neoadjuvant chemotherapy, effective treatment of osteosarcoma has not improved over the last four decades. With the advent of immunotherapy, the treatment paradigm has now changed. The latest clinical studies show a slight improvement compared to conventional polychemotherapy.

(red) Benign and malignant primary bone tumors are classified according to the type of tissue from which the tumor originates. Malignant primary bone tumors, also known as bone sarcomas, are a group of rare malignant diseases originating in the skeletal system with a prevalence in the long bones. Bone sarcomas are very aggressive and patients suffer from pain, swelling and bone fractures. These tumors are difficult to treat, exhibit numerous histological variations and cause many clinical difficulties in the search for suitable therapies. The three most important entities of bone sarcomas are osteosarcomas (OS), Ewing’s sarcomas and chondrosarcomas.

OS are the most common malignant bone tumors in adolescents and young adults. They are mainly localized in the metaphysis of the long bones, particularly in the distal femur, proximal tibia and humerus. They originate from primitive mesenchymal cells and are characterized by the formation of an immature extracellular osteoid matrix associated with bone resorption mediated by activated osteoclasts. The biological origin of OS remains unclear, although several factors may be responsible for the disease, including genetic mutations and an immunosuppressive microenvironment that promotes tumor development. The lung parenchyma is the most common site of metastasis in OS, and metastatic foci are often associated with a poor clinical outcome. Conventional treatment of OS is based on a sequential approach that combines chemotherapy and surgery. Due to the particular radioresistance of OS, radiotherapy is only suggested for tumors in high-risk locations or to reduce the risk of recurrence after surgery. Despite the increase in clinical trials over the last four decades, cure rates have not improved. Non-specific targeted therapies therefore show a poor therapeutic effect with side effects at high doses.

Immunotherapies as a new treatment approach

Tumor cells are able to stimulate the tumor microenvironment (TME) to suppress the antitumor immune system, leading to tumor drug resistance. The development of personalized precision medicine in recent decades, including immunotherapies, has shown enormous benefits in the treatment of malignant tumors. As the successful treatment of metastatic melanoma with ipilimumab shows, several immune checkpoint inhibitors have been approved by the FDA. The main list of immune checkpoint inhibitors includes programmed death-1 (PD-1), death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) – and all are theoretically therapeutic options in OS. However, OS is described as a “cold tumor” in terms of low local immune activation and recognition of cancer cells, even when detectable immune cells are present in the tumor microenvironment. This immunotolerant environment may be explained by mechanisms of adaptive immune resistance (higher expression of PD-L1, CTLA-4 and IDO1) and the presence of myeloid-derived suppressor cells that inhibit T cell activation and enhance immune evasion of OS. Overall, the use of immune checkpoint inhibitors (monotherapy or dual therapy) has limited clinical value. It is therefore crucial to clarify the mechanisms of action associated with this immune response desert in order to reverse local immunity in OS.

Deciphering the key functions of each tumor microenvironment will allow us to understand the local immune tolerance observed in OS, although immune infiltrates in tumor tissue have been described. OS is a heterogeneous tumor that is regulated by its microenvironment and has a counterproductive effect. Research in this field is carried out on 2D surfaces. Mimicking the 3D shape of OS could lead to reproducible and applicable results.

Further reading:

  • Panez-Toro I, Muñoz-García J, Vargas-Franco JW, et al: Advances in Osteosarcoma. Curr Osteoporos Rep 2023 Aug; 21(4): 330-343.

InFo ONCOLOGY & HEMATOLOGY 2024; 12(1): 32

Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • bone tumor
  • Immunotherapy
  • Osteosarcoma
You May Also Like
View Post
  • 6 min
  • When the bones become more fragile: “Case Finding”

Fracture risk reduction in osteoporosis

    • Congress Reports
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • Rheumatology
    • RX
    • Studies
View Post
  • 6 min
  • Biologics for plaque psoriasis

What increases the chance of a sustained remission?

    • Congress Reports
    • Dermatology and venereology
    • Rheumatology
    • RX
    • Studies
View Post
  • 16 min
  • Pain and autism

Hurdles to pain treatment for autistic patients

    • CME continuing education
    • Pediatrics
    • Pharmacology and toxicology
    • Psychiatry and psychotherapy
    • RX
    • Studies
View Post
  • 12 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • CME continuing education
    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 5 min
  • Long-COVID

Increased risk with asthma and COPD

    • Education
    • General Internal Medicine
    • Pneumology
    • RX
    • Studies
View Post
  • 10 min
  • Atopic dermatitis in children

New secondary analysis on dietary interventions

    • Dermatology and venereology
    • Education
    • Nutrition
    • Pediatrics
    • Pharmaceutical medicine
    • RX
    • Studies
View Post
  • 4 min
  • Case report: bronchobiliary fistula

Disguised as pneumonia

    • Cases
    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Pneumology
    • RX
View Post
  • 5 min
  • Rehospitalization risk for cardiopulmonary diseases

Transition to the outpatient setting is crucial

    • Congress Reports
    • General Internal Medicine
    • Pneumology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Hurdles to pain treatment for autistic patients
  • 2
    Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
  • 3
    Treatment of comorbidities in older people
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Rare malignancy from a dermatological perspective

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.